MA46752A - Traitement de maladies du snc au moyen de stimulateurs de gcs - Google Patents
Traitement de maladies du snc au moyen de stimulateurs de gcsInfo
- Publication number
- MA46752A MA46752A MA046752A MA46752A MA46752A MA 46752 A MA46752 A MA 46752A MA 046752 A MA046752 A MA 046752A MA 46752 A MA46752 A MA 46752A MA 46752 A MA46752 A MA 46752A
- Authority
- MA
- Morocco
- Prior art keywords
- gcs
- stimulators
- treatment
- cns diseases
- cns
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419059P | 2016-11-08 | 2016-11-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46752A true MA46752A (fr) | 2019-09-18 |
Family
ID=60452769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046752A MA46752A (fr) | 2016-11-08 | 2017-11-07 | Traitement de maladies du snc au moyen de stimulateurs de gcs |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11690828B2 (enExample) |
| EP (1) | EP3538096B1 (enExample) |
| JP (2) | JP7150740B2 (enExample) |
| KR (1) | KR102475124B1 (enExample) |
| CN (1) | CN110267658B (enExample) |
| AU (2) | AU2017359018C1 (enExample) |
| BR (1) | BR112019009449A2 (enExample) |
| CA (1) | CA3042548A1 (enExample) |
| CL (1) | CL2019001256A1 (enExample) |
| EA (1) | EA201991147A1 (enExample) |
| ES (1) | ES2972711T3 (enExample) |
| IL (1) | IL266275B2 (enExample) |
| MA (1) | MA46752A (enExample) |
| MX (2) | MX2019005342A (enExample) |
| NZ (1) | NZ753434A (enExample) |
| PH (1) | PH12019501016A1 (enExample) |
| SG (1) | SG10202104865UA (enExample) |
| TW (1) | TWI812601B (enExample) |
| WO (1) | WO2018089328A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110267949A (zh) * | 2016-11-08 | 2019-09-20 | 塞科里昂医疗股份有限公司 | sGC刺激剂 |
| WO2019055859A1 (en) * | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
| KR20210031931A (ko) | 2018-07-11 | 2021-03-23 | 사이클리온 테라퓨틱스, 인크. | 미토콘드리아 장애의 치료를 위한 sGC 자극제의 용도 |
| US20220087970A1 (en) * | 2019-01-18 | 2022-03-24 | The Johns Hopkins University | Prevention of anesthetic-induced neurocognitive dysfunction |
| CN114929207A (zh) * | 2019-12-05 | 2022-08-19 | 载度思生命科学有限公司 | 利奥西呱的调节释放型药物组合物 |
| JP7412583B2 (ja) | 2020-02-07 | 2024-01-12 | ニューロヴェンティ カンパニー リミテッド | リルメニジン化合物を有効成分として含む脆弱ｘ症候群または関連発達障害を治療するための組成物 |
| CN112924573B (zh) * | 2021-01-21 | 2022-01-04 | 山东英盛生物技术有限公司 | 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法 |
| EP4456897A4 (en) * | 2021-12-31 | 2025-12-10 | Tenax Therapeutics Inc | ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION |
| EP4658253A1 (en) * | 2023-02-03 | 2025-12-10 | R.P. Scherer Technologies, LLC | Osmotic pharmaceutical capsules |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| EP0192963B1 (de) | 1985-02-27 | 1988-07-20 | Werkzeugmaschinenfabrik Oerlikon-Bührle AG | Schwingungsmesseinrichtung für ein Spiralkegelradgetriebe auf einer Zahnradprüfmaschine |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| HU228111B1 (en) | 1998-07-08 | 2012-11-28 | Sanofi Aventis Deutschland | Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| CN1161101C (zh) | 1998-12-17 | 2004-08-11 | 阿尔扎有限公司 | 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统 |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| KR20060033033A (ko) | 2003-08-04 | 2006-04-18 | 화이자 프로덕츠 인크. | 콜레스테릴 에스테르 전달 단백질 억제제의 제어 방출 및ｈｍｇ-ｃｏａ 리덕타제 억제제의 순간 방출을 제공하는제형 |
| DE102006020327A1 (de) * | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
| BRPI0816382A2 (pt) | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
| JP2011510082A (ja) | 2008-01-24 | 2011-03-31 | メルク・シャープ・エンド・ドーム・コーポレイション | アンジオテンシンｉｉ受容体拮抗薬 |
| AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| AU2010218224B2 (en) | 2009-02-26 | 2013-06-27 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US9284301B2 (en) | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EA023254B1 (ru) | 2010-05-27 | 2016-05-31 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA3006764A1 (en) * | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of gastrointestinal sphincter dysfunction |
| WO2017108441A1 (en) | 2015-12-22 | 2017-06-29 | Universiteit Maastricht | Treatment of cognitive impairment with cgc stimulator |
| WO2017121700A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
| CR20220309A (es) * | 2016-09-02 | 2022-09-16 | Cyclerion Therapeutics Inc | Estimuladores de sgc |
-
2017
- 2017-11-07 TW TW106138467A patent/TWI812601B/zh active
- 2017-11-07 WO PCT/US2017/060299 patent/WO2018089328A1/en not_active Ceased
- 2017-11-07 ES ES17804374T patent/ES2972711T3/es active Active
- 2017-11-07 JP JP2019545723A patent/JP7150740B2/ja active Active
- 2017-11-07 SG SG10202104865UA patent/SG10202104865UA/en unknown
- 2017-11-07 KR KR1020197016351A patent/KR102475124B1/ko active Active
- 2017-11-07 US US16/348,359 patent/US11690828B2/en active Active
- 2017-11-07 NZ NZ753434A patent/NZ753434A/en unknown
- 2017-11-07 CN CN201780080543.0A patent/CN110267658B/zh active Active
- 2017-11-07 AU AU2017359018A patent/AU2017359018C1/en active Active
- 2017-11-07 MA MA046752A patent/MA46752A/fr unknown
- 2017-11-07 EP EP17804374.1A patent/EP3538096B1/en active Active
- 2017-11-07 BR BR112019009449A patent/BR112019009449A2/pt not_active IP Right Cessation
- 2017-11-07 CA CA3042548A patent/CA3042548A1/en active Pending
- 2017-11-07 EA EA201991147A patent/EA201991147A1/ru unknown
- 2017-11-07 IL IL266275A patent/IL266275B2/en unknown
- 2017-11-07 MX MX2019005342A patent/MX2019005342A/es unknown
-
2019
- 2019-05-07 CL CL2019001256A patent/CL2019001256A1/es unknown
- 2019-05-07 MX MX2022010852A patent/MX2022010852A/es unknown
- 2019-05-08 PH PH12019501016A patent/PH12019501016A1/en unknown
-
2022
- 2022-08-08 JP JP2022126467A patent/JP2022160605A/ja active Pending
-
2023
- 2023-05-12 US US18/196,826 patent/US20230381153A1/en not_active Abandoned
- 2023-11-22 AU AU2023270267A patent/AU2023270267A1/en not_active Abandoned
-
2024
- 2024-07-31 US US18/790,576 patent/US20250108040A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46752A (fr) | Traitement de maladies du snc au moyen de stimulateurs de gcs | |
| EP3548039A4 (en) | METHODS FOR TREATMENT OF DISEASES RELATED TO MITOCHONDRIAL STRESS | |
| MA47095A (fr) | Traitement du palais mou | |
| EP3389725A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
| EP3448875A4 (en) | Compositions for the treatment of disease | |
| EP3875139C0 (en) | TREATMENT OF VENOUS DISEASES | |
| EP3390634A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES | |
| EP3454945A4 (en) | ASH11 INHIBITORS AND METHOD FOR TREATING THEM | |
| EP3720553C0 (en) | PHOTOBIOMODULATION DEVICE FOR THE TREATMENT OF A RETINAL DISEASE | |
| EP3370703A4 (en) | GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES | |
| EP3658139A4 (en) | Methods for treating liver diseases | |
| EP3634442A4 (en) | METHODS OF TREATMENT AND PREVENTION OF DISEASES | |
| FR25C1031I1 (fr) | Traitement de maladies cholestatiques intrahepatiques | |
| EP2975055A4 (en) | C5 ANTIBODIES AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-MEDIATED ILLNESSES | |
| EP3273955A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
| EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
| EP3390666A4 (en) | COMPOSITIONS AND METHODS OF TREATING NURSE DISEASES | |
| MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
| EP3448263A4 (en) | Electrotherapeutic treatment | |
| EP3432888A4 (en) | CANCER TREATMENT WITH TG02 | |
| EP3294274A4 (en) | TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM WITH CAPSULATED INDUCIBLE PLEXUS CHOROIDEUS CELLS | |
| EP3364974A4 (en) | MODULATORS OF TELOMIC DISEASE | |
| DK3104852T3 (da) | Sammensætninger og fremgangsmåde til behandling af aldring og aldersbetingede sygdomme og symptomer | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| MA41462A (fr) | Méthode de traitement de maladies |